CA1276143C - Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues - Google Patents
Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissuesInfo
- Publication number
- CA1276143C CA1276143C CA000499104A CA499104A CA1276143C CA 1276143 C CA1276143 C CA 1276143C CA 000499104 A CA000499104 A CA 000499104A CA 499104 A CA499104 A CA 499104A CA 1276143 C CA1276143 C CA 1276143C
- Authority
- CA
- Canada
- Prior art keywords
- hyaluronic acid
- water
- tissue
- solvent
- chemically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 27
- 241001465754 Metazoa Species 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 238000011084 recovery Methods 0.000 title description 9
- 239000000203 mixture Substances 0.000 claims abstract description 64
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 238000004132 cross linking Methods 0.000 claims abstract description 12
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 12
- 238000011065 in-situ storage Methods 0.000 claims abstract description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 69
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 52
- 210000001520 comb Anatomy 0.000 claims description 49
- 239000000284 extract Substances 0.000 claims description 47
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 44
- 229920000642 polymer Polymers 0.000 claims description 34
- 239000002904 solvent Substances 0.000 claims description 33
- 238000000605 extraction Methods 0.000 claims description 28
- 241000287828 Gallus gallus Species 0.000 claims description 23
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 22
- 239000011780 sodium chloride Substances 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 16
- 239000003792 electrolyte Substances 0.000 claims description 14
- 238000001556 precipitation Methods 0.000 claims description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 9
- 150000001299 aldehydes Chemical class 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 239000001632 sodium acetate Substances 0.000 claims description 9
- 235000017281 sodium acetate Nutrition 0.000 claims description 9
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000007385 chemical modification Methods 0.000 claims description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical group O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 4
- 229940015043 glyoxal Drugs 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 238000010908 decantation Methods 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- 239000011541 reaction mixture Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 229940113088 dimethylacetamide Drugs 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 235000011007 phosphoric acid Nutrition 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 235000011149 sulphuric acid Nutrition 0.000 claims 1
- 239000003799 water insoluble solvent Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 25
- 108090000623 proteins and genes Proteins 0.000 abstract description 25
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 11
- 229940072322 hylan Drugs 0.000 abstract description 5
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 96
- 239000000243 solution Substances 0.000 description 84
- 239000000047 product Substances 0.000 description 63
- 210000001519 tissue Anatomy 0.000 description 58
- 230000000670 limiting effect Effects 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 229940022682 acetone Drugs 0.000 description 21
- 239000000126 substance Substances 0.000 description 17
- 235000019624 protein content Nutrition 0.000 description 16
- 229920002521 macromolecule Polymers 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 229960001701 chloroform Drugs 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 230000010355 oscillation Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000001974 Hyaluronidases Human genes 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- -1 e.g. Substances 0.000 description 5
- 108010003272 Hyaluronate lyase Proteins 0.000 description 4
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- YIBPLYRWHCQZEB-UHFFFAOYSA-N formaldehyde;propan-2-one Chemical compound O=C.CC(C)=O YIBPLYRWHCQZEB-UHFFFAOYSA-N 0.000 description 4
- 229960002773 hyaluronidase Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229940037395 electrolytes Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- IAJILQKETJEXLJ-KLVWXMOXSA-N (2s,3r,4r,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-KLVWXMOXSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- YCDPDGHFGPRDNH-UHFFFAOYSA-M C(C)(=O)[O-].[Na+].CC(=O)C Chemical compound C(C)(=O)[O-].[Na+].CC(=O)C YCDPDGHFGPRDNH-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- HLVXFWDLRHCZEI-UHFFFAOYSA-N chromotropic acid Chemical compound OS(=O)(=O)C1=CC(O)=C2C(O)=CC(S(O)(=O)=O)=CC2=C1 HLVXFWDLRHCZEI-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 150000002016 disaccharides Chemical group 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 229940089982 healon Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940070376 protein Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 108050009363 Hyaluronidases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001408653 Siona Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000001374 small-angle light scattering Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960004319 trichloroacetic acid Drugs 0.000 description 1
- 238000000196 viscometry Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/710,929 US4713448A (en) | 1985-03-12 | 1985-03-12 | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
| US710,929 | 1985-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1276143C true CA1276143C (en) | 1990-11-13 |
Family
ID=24856100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000499104A Expired - Lifetime CA1276143C (en) | 1985-03-12 | 1986-01-07 | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
Country Status (12)
Families Citing this family (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US5099013A (en) * | 1985-03-12 | 1992-03-24 | Biomatrix, Inc, | Hylan preparation and method of recovery thereof from animal tissues |
| EP0221167A4 (en) * | 1985-05-09 | 1988-08-24 | David Cullis-Hill | PRODUCTION OF HYALURONIC ACID. |
| US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| EP0224987B1 (en) * | 1985-11-29 | 1992-04-15 | Biomatrix, Inc. | Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same |
| SE452469B (sv) * | 1986-06-18 | 1987-11-30 | Pharmacia Ab | Material bestaende av en tverbunden karboxylgrupphaltig polysackarid och forfarande vid framstellning av detsamma |
| IT1198449B (it) * | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
| AU610512B2 (en) * | 1986-12-11 | 1991-05-23 | Biomatrix Incorporated | Improved hyaluronate-poly (ethylene oxide) mixtures |
| GB8713662D0 (en) * | 1987-06-11 | 1987-07-15 | Skandigen Ab | Hyaluronic acid derivatives |
| US6610669B1 (en) | 1987-09-18 | 2003-08-26 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
| US6174999B1 (en) | 1987-09-18 | 2001-01-16 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
| AU619760B2 (en) * | 1987-12-10 | 1992-02-06 | Genzyme Biosurgery Corporation | Hylan preparation and method of recovery thereof from animal tissues |
| IT1219587B (it) * | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | Polisaccaridi carbossiilici autoreticolati |
| US5112615A (en) * | 1988-08-03 | 1992-05-12 | New England Deaconess Hospital Corporation | Soluble hirudin conjugates |
| US5356883A (en) * | 1989-08-01 | 1994-10-18 | Research Foundation Of State University Of N.Y. | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
| US5143724A (en) * | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
| US5246698A (en) * | 1990-07-09 | 1993-09-21 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
| US5990096A (en) * | 1990-09-18 | 1999-11-23 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US5824658A (en) * | 1990-09-18 | 1998-10-20 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
| CA2061703C (en) * | 1992-02-20 | 2002-07-02 | Rudolf E. Falk | Formulations containing hyaluronic acid |
| US5910489A (en) * | 1990-09-18 | 1999-06-08 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
| US5219360A (en) * | 1991-05-10 | 1993-06-15 | Fortis Research Corporation | Mammary prosthesis fill and method of making same |
| US5977088A (en) * | 1991-07-03 | 1999-11-02 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US5792753A (en) * | 1991-07-03 | 1998-08-11 | Hyal Pharmaceutical Corporation | Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs |
| US6103704A (en) * | 1991-07-03 | 2000-08-15 | Hyal Pharmaceutical Corporation | Therapeutic methods using hyaluronic acid |
| CA2061567C (en) * | 1992-02-20 | 1998-02-03 | Rudolf E. Falk | Use of hyaluronic acid to repair ischemia reperfusion damage |
| US6218373B1 (en) | 1992-02-20 | 2001-04-17 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US5767106A (en) * | 1992-02-21 | 1998-06-16 | Hyal Pharmaceutical Corporation | Treatment of disease and conditions associated with macrophage infiltration |
| IT1260154B (it) * | 1992-07-03 | 1996-03-28 | Lanfranco Callegaro | Acido ialuronico e suoi derivati in polimeri interpenetranti (ipn) |
| US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
| US5690961A (en) * | 1994-12-22 | 1997-11-25 | Hercules Incorporated | Acidic polysaccharides crosslinked with polycarboxylic acids and their uses |
| US5612321A (en) * | 1995-06-22 | 1997-03-18 | Hercules Incorporated | Antioxidant grafted polysaccharides |
| CA2273852C (en) | 1996-12-06 | 2009-09-29 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6630457B1 (en) * | 1998-09-18 | 2003-10-07 | Orthogene Llc | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same |
| IT1303738B1 (it) * | 1998-11-11 | 2001-02-23 | Aquisitio S P A | Processo di reticolazione di polisaccaridi carbossilati. |
| US20040048021A1 (en) * | 1999-03-19 | 2004-03-11 | Wan Barbara Y. F. | Surface modification of substrates |
| US6610666B1 (en) | 1999-11-08 | 2003-08-26 | Bio-Hyos Ab | Hyaluronan product and process for manufacturing thereof |
| US6521223B1 (en) | 2000-02-14 | 2003-02-18 | Genzyme Corporation | Single phase gels for the prevention of adhesions |
| KR100375299B1 (ko) | 2000-10-10 | 2003-03-10 | 주식회사 엘지생명과학 | 히알루론산의 가교결합형 아마이드 유도체와 이의 제조방법 |
| WO2002068383A2 (en) * | 2001-02-22 | 2002-09-06 | Anika Therapeutics, Inc. | Thiol-modified hyaluronan |
| KR100514582B1 (ko) * | 2001-09-05 | 2005-09-13 | 한스바이오메드 주식회사 | 생체복원물질의 제조방법 |
| MXPA01011542A (es) * | 2001-11-13 | 2003-05-22 | Alcon Inc | Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel. |
| US7186232B1 (en) * | 2002-03-07 | 2007-03-06 | Glaukoa Corporation | Fluid infusion methods for glaucoma treatment |
| KR20100110378A (ko) | 2002-05-24 | 2010-10-12 | 안지오테크 인터내셔날 아게 | 의료용 임플란트를 피복하기 위한 조성물 및 방법 |
| US8313760B2 (en) | 2002-05-24 | 2012-11-20 | Angiotech International Ag | Compositions and methods for coating medical implants |
| EP1539799B1 (en) * | 2002-06-21 | 2013-12-11 | The University of Utah Research Foundation | Crosslinked compounds and methods of making and using thereof |
| KR100954311B1 (ko) * | 2002-08-16 | 2010-04-21 | 덴끼 가가꾸 고교 가부시키가이샤 | 분리형 의료 재료 |
| KR20040022760A (ko) * | 2002-09-05 | 2004-03-18 | 주식회사 오스코텍 | 닭벼슬로부터 고순도 히아루론산의 추출방법 |
| US20040180025A1 (en) * | 2003-03-12 | 2004-09-16 | New Life Resources, Llc | Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations |
| US20080063677A1 (en) * | 2004-03-10 | 2008-03-13 | New Life Resources, Llc | Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations |
| US6946551B2 (en) * | 2003-03-12 | 2005-09-20 | New Life Resources, Llc | Preparation of hyaluronic acid from eggshell membrane |
| FR2861734B1 (fr) | 2003-04-10 | 2006-04-14 | Corneal Ind | Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| JP2007514472A (ja) * | 2003-11-20 | 2007-06-07 | アンジオテック インターナショナル アーゲー | 軟組織移植片および瘢痕化抑制剤 |
| US20080176205A1 (en) * | 2003-12-04 | 2008-07-24 | University Of Utah Research Foundation | Process and Formulation to Improve Viability of Stored Cells and Tissue |
| US7091191B2 (en) * | 2003-12-19 | 2006-08-15 | Ethicon, Inc. | Modified hyaluronic acid for use in musculoskeletal tissue repair |
| US7625581B2 (en) * | 2003-12-19 | 2009-12-01 | Ethicon, Inc. | Tissue scaffolds for use in muscoloskeletal repairs |
| US20050142152A1 (en) * | 2003-12-30 | 2005-06-30 | Leshchiner Adelya K. | Polymeric materials, their preparation and use |
| US8524213B2 (en) * | 2003-12-30 | 2013-09-03 | Genzyme Corporation | Polymeric materials, their preparation and use |
| DE102004002001A1 (de) * | 2004-01-14 | 2005-08-11 | Reinmüller, Johannes, Dr.med. | Mittel zur Behandlung von entzündlichen Erkrankungen |
| US8580315B2 (en) * | 2004-03-10 | 2013-11-12 | Esm Technologies, Llc | Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations |
| US20050281880A1 (en) * | 2004-05-20 | 2005-12-22 | Wei Wang | Methods for making injectable polymer hydrogels |
| US7002007B2 (en) * | 2004-05-28 | 2006-02-21 | Calcigen Corporation | Production of high molecular weight hyaluronates |
| ITMI20041373A1 (it) | 2004-07-09 | 2004-10-09 | Lima Lto S P A | N-metil-ammidi di carbossimetilcellulosa acido alginico o carbossimetalamido |
| PT1817347T (pt) | 2004-11-24 | 2017-07-21 | Albumedix As | Resumo |
| PL1835923T3 (pl) | 2004-12-30 | 2014-03-31 | Genzyme Corp | Schematy wiskosuplementacji dostawowej |
| ITPD20050056A1 (it) | 2005-03-02 | 2006-09-03 | Fidia Farmaceutici | Derivati ammidici del'acido ialuronico in osteoartrosi |
| AU2006292224B2 (en) | 2005-09-19 | 2013-08-01 | Histogenics Corporation | Cell-support matrix and a method for preparation thereof |
| CA2633957A1 (en) * | 2005-12-14 | 2007-06-21 | Anika Therapeutics, Inc. | Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid |
| US20070202084A1 (en) | 2005-12-14 | 2007-08-30 | Anika Therapeutics, Inc. | Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects |
| JP5227196B2 (ja) | 2006-03-07 | 2013-07-03 | プロコン バイオテック リミテッド | ヒアルロン酸のヒドラジド誘導体 |
| ITPD20060219A1 (it) | 2006-05-31 | 2007-12-01 | Fidia Farmaceutici | Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi |
| ES2391862T3 (es) * | 2006-12-22 | 2012-11-30 | Croma-Pharma Gesellschaft M.B.H. | Uso de polisacaridos tiolados para el aumento de tejido |
| US8329870B2 (en) * | 2007-01-04 | 2012-12-11 | Hepacore Ltd. | Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof |
| JP2010528046A (ja) | 2007-05-23 | 2010-08-19 | アラーガン、インコーポレイテッド | 架橋コラーゲンおよびその使用 |
| US8658148B2 (en) | 2007-06-22 | 2014-02-25 | Genzyme Corporation | Chemically modified dendrimers |
| US20110077737A1 (en) * | 2007-07-30 | 2011-03-31 | Allergan, Inc. | Tunably Crosslinked Polysaccharide Compositions |
| US8318695B2 (en) | 2007-07-30 | 2012-11-27 | Allergan, Inc. | Tunably crosslinked polysaccharide compositions |
| US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
| WO2009063291A1 (en) * | 2007-11-13 | 2009-05-22 | Bio-Technology General (Israel) Ltd. | Dilute filtration sterilization process for viscoelastic biopolymers |
| HUE042931T2 (hu) | 2007-11-16 | 2019-07-29 | Aclaris Therapeutics Inc | Kompozíciók és eljárások purpura kezelésére |
| US8394784B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
| US8394782B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
| US9161970B2 (en) | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
| US9044477B2 (en) | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
| EP2222715B1 (en) * | 2007-12-19 | 2019-07-24 | Evonik Degussa GmbH | Crosslinked hyaluronic acid in emulsion |
| US8357795B2 (en) | 2008-08-04 | 2013-01-22 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
| ES2658609T3 (es) | 2008-09-02 | 2018-03-12 | Tautona Group Lp | Hilos de ácido hialurónico y/o derivados de los mismos, métodos para fabricar los mismos, y usos de los mismos |
| US8624077B2 (en) | 2008-10-02 | 2014-01-07 | L.R.R.&D. Ltd. | Interface layer wound dressing |
| CN101721349B (zh) | 2008-10-16 | 2011-07-20 | 常州百瑞吉生物医药有限公司 | 可注射原位交联水凝胶及其制备方法和用途 |
| CZ301555B6 (cs) | 2008-11-06 | 2010-04-14 | Cpn S. R. O. | Zpusob prípravy DTPA sítovaných derivátu kyseliny hyaluronové a jejich modifikace |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US8273725B2 (en) | 2009-09-10 | 2012-09-25 | Genzyme Corporation | Stable hyaluronan/steroid formulation |
| CZ2009835A3 (cs) | 2009-12-11 | 2011-06-22 | Contipro C A.S. | Zpusob prípravy derivátu kyseliny hyaluronové oxidovaného v poloze 6 glukosaminové cásti polysacharidu selektivne na aldehyd a zpusob jeho modifikace |
| CZ2009836A3 (cs) | 2009-12-11 | 2011-06-22 | Contipro C A.S. | Derivát kyseliny hyaluronové oxidovaný v poloze 6 glukosaminové cásti polysacharidu selektivne na aldehyd, zpusob jeho prípravy a zpusob jeho modifikace |
| US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
| US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
| CA2792729C (en) | 2010-03-12 | 2016-06-28 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
| US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
| US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
| US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| CZ20101001A3 (cs) | 2010-12-31 | 2012-02-08 | Cpn S.R.O. | Hyaluronová vlákna, zpusob jejich prípravy a použití |
| WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
| CA3133676A1 (en) | 2011-06-03 | 2012-12-06 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
| US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
| US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
| US20130096081A1 (en) | 2011-06-03 | 2013-04-18 | Allergan, Inc. | Dermal filler compositions |
| DE102011077393A1 (de) * | 2011-06-10 | 2012-12-13 | Johannes Reinmüller | Antiinfektives Mittel |
| US10865383B2 (en) | 2011-07-12 | 2020-12-15 | Lineage Cell Therapeutics, Inc. | Methods and formulations for orthopedic cell therapy |
| ES2899992T3 (es) | 2011-08-10 | 2022-03-15 | Glycores 2000 Srl | Acido hialurónico reticulado de bajo peso molecular resistente a la degradación |
| US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| US9662422B2 (en) | 2011-09-06 | 2017-05-30 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
| FR2983483B1 (fr) | 2011-12-02 | 2014-11-14 | Vivacy Lab | Procede de substitution et reticulation simultanees d'un polysaccharide via ses fonctions hydroxyles |
| CZ2012136A3 (cs) | 2012-02-28 | 2013-06-05 | Contipro Biotech S.R.O. | Deriváty na bázi kyseliny hyaluronové schopné tvorit hydrogely, zpusob jejich prípravy, hydrogely na bázi techto derivátu, zpusob jejich prípravy a pouzití |
| KR101240518B1 (ko) | 2012-03-26 | 2013-03-11 | 주식회사 제네웰 | 생체 적합성 고분자를 이용한 이식용 재료 |
| PL2831237T3 (pl) | 2012-03-30 | 2018-06-29 | The Board Of Regents Of The University Of Oklahoma | Polimery heparosanu o wysokiej masie cząsteczkowej i sposoby ich wytwarzania i zastosowania |
| ITPD20120098A1 (it) | 2012-03-30 | 2013-10-01 | Fidia Farmaceutici | "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico" |
| ITPD20120173A1 (it) | 2012-05-31 | 2013-12-01 | Fidia Farmaceutici | "nuovo sistema di rilascio di proteine idrofobiche" |
| PL2861626T3 (pl) | 2012-06-15 | 2019-05-31 | Merz Pharma Gmbh & Co Kgaa | Sposób przygotowywania kompozycji na bazie kwasu hialuronowego |
| CZ304512B6 (cs) | 2012-08-08 | 2014-06-11 | Contipro Biotech S.R.O. | Derivát kyseliny hyaluronové, způsob jeho přípravy, způsob jeho modifikace a použití |
| CN102863631B (zh) * | 2012-09-29 | 2013-11-13 | 杭州嘉伟生物制品有限公司 | 外科整形用组织填充剂交联透明质酸钠凝胶及其制备方法 |
| CZ2012842A3 (cs) | 2012-11-27 | 2014-08-20 | Contipro Biotech S.R.O. | Nanomicelární kompozice na bázi C6-C18-acylovaného hyaluronanu, způsob přípravy C6-C18-acylovaného hyaluronanu, způsob přípravy nanomicelární kompozice a stabilizované nanomicelární kompozice a použití |
| EP2943531A1 (en) | 2013-01-11 | 2015-11-18 | Carbylan Therapeutics, Inc. | Stabilized compositions comprising hyaluronic acid |
| US9714361B2 (en) | 2013-03-15 | 2017-07-25 | Lake Region Manfacturing, Inc. | Oxirane (ethylene oxide) polyurethane coatings |
| US9255173B2 (en) | 2013-03-15 | 2016-02-09 | Lake Region Manufacturing, Inc. | Oxirane (ethylene oxide) polyurethane coatings |
| CZ2014150A3 (cs) | 2014-03-11 | 2015-05-20 | Contipro Biotech S.R.O. | Konjugáty oligomeru kyseliny hyaluronové nebo její soli, způsob jejich přípravy a použití |
| CZ2014451A3 (cs) | 2014-06-30 | 2016-01-13 | Contipro Pharma A.S. | Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití |
| EP3200838B1 (en) | 2014-09-30 | 2019-09-18 | Allergan Industrie, SAS | Stable hydrogel compositions including additives |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
| WO2016128783A1 (en) | 2015-02-09 | 2016-08-18 | Allergan Industrie Sas | Compositions and methods for improving skin appearance |
| HUE047971T2 (hu) | 2015-02-13 | 2020-05-28 | Allergan Ind Sas | Az arcelemek - például az áll - formázására, megnagyobbítására vagy korrekciójára szolgáló implantátumok |
| CZ309295B6 (cs) | 2015-03-09 | 2022-08-10 | Contipro A.S. | Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití |
| CZ306479B6 (cs) | 2015-06-15 | 2017-02-08 | Contipro A.S. | Způsob síťování polysacharidů s využitím fotolabilních chránicích skupin |
| CZ306662B6 (cs) | 2015-06-26 | 2017-04-26 | Contipro A.S. | Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití |
| KR20170090965A (ko) * | 2016-01-29 | 2017-08-08 | 한미약품 주식회사 | 복합 히알루론산 가교물 및 그 제조방법 |
| EP4166145B1 (en) | 2016-02-12 | 2025-07-09 | Laimu Corporation | Method for producing a nerve growth factor, water-saturated 1-butanol fraction prepared by the method, internal preparation and liquid external preparation |
| CZ308106B6 (cs) | 2016-06-27 | 2020-01-08 | Contipro A.S. | Nenasycené deriváty polysacharidů, způsob jejich přípravy a jejich použití |
| EP3578573A4 (en) | 2017-02-02 | 2020-11-18 | Amtixbio Co., Ltd. | HYDROGEL USING AS A SUBSTRATE A HYALURONIC ACID DERIVATIVE MODIFIED BY A GALLOL GROUP, AND ASSOCIATED USE |
| US20200108129A1 (en) | 2018-09-13 | 2020-04-09 | Allergan, Inc. | Clostridial toxin - hyaluronic acid compositions |
| US10899944B2 (en) | 2018-10-29 | 2021-01-26 | Lake Region Manufacturing, Inc. | Polyurethane urea-containing adipic acid dihydrazide where active hydrogens react with the epoxy group found on glycidol to form a diol |
| JP7555924B2 (ja) | 2018-12-07 | 2024-09-25 | ハンミ ファーマシューティカルズ カンパニー リミテッド | ヒアルロン酸架橋物、ヒアルロン酸水和ゲル、及びそれらの製造方法 |
| KR102400586B1 (ko) | 2018-12-07 | 2022-05-23 | 한미약품 주식회사 | 히알루론산 가교물, 히알루론산 수화 겔 및 이들의 제조방법 |
| EP4271433A4 (en) | 2020-12-30 | 2024-11-13 | ConvaTec Technologies Inc. | SURFACE TREATMENT SYSTEM AND METHOD FOR SUBCUTANEOUS DEVICE |
| KR20220106283A (ko) | 2021-01-22 | 2022-07-29 | (주)앰틱스바이오 | 자가 가교형 히알루론산 유도체 기반 창상피복재 |
| DE102022202547A1 (de) | 2021-12-09 | 2023-06-15 | Beiersdorf Aktiengesellschaft | Topisch applizierbare Zubereitung zur Verbesserung des Hautzustandes |
| EP4444418A1 (de) | 2021-12-09 | 2024-10-16 | Beiersdorf AG | Topisch applizierbare zubereitung zur verbesserung des hautzustandes |
| IT202100032111A1 (it) | 2021-12-22 | 2023-06-22 | Fidia Farm Spa | Nuovi sostituti biocompatibili dell’umor vitreo |
| DE102023201536A1 (de) | 2023-02-21 | 2024-08-22 | Beiersdorf Aktiengesellschaft | Körpermilch |
| DE102023201528A1 (de) | 2023-02-21 | 2024-08-22 | Beiersdorf Aktiengesellschaft | Körpermilch |
| DE102023203936A1 (de) | 2023-04-27 | 2024-10-31 | Beiersdorf Aktiengesellschaft | Retinolhaltige kosmetische Zubereitung mit guter Hautverträglichkeit |
| WO2024223513A1 (de) | 2023-04-27 | 2024-10-31 | Beiersdorf Ag | Retinolhaltige kosmetische zubereitung mit guter hautverträglichkeit |
| WO2024223515A1 (de) | 2023-04-27 | 2024-10-31 | Beiersdorf Ag | Retinolhaltige kosmetische zubereitung mit guter stabilität und hautverträglichkeit |
| WO2024223517A1 (de) | 2023-04-27 | 2024-10-31 | Beiersdorf Ag | Retinolhaltige kosmetische zubereitung mit guter stabilität, hautverträglichkeit und wirksamkeit |
| CN118812877B (zh) * | 2024-06-17 | 2025-02-14 | 弘知生物科技(浙江)有限公司 | 一种含聚胍类高分子聚合物的长效抑菌水凝胶及制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT252264B (de) * | 1965-03-17 | 1967-02-10 | Etapharm Chem Pharm Lab Ges M | Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates |
| US4152170A (en) * | 1975-06-18 | 1979-05-01 | Sumitomo Chemical Company, Ltd. | Cross-linked pullulan |
| US4141973A (en) * | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
| US4048435A (en) * | 1976-07-12 | 1977-09-13 | National Starch And Chemical Corporation | Method for the preparation of highly substituted granular starches |
| US4272522A (en) * | 1979-10-15 | 1981-06-09 | Balazs Endre A | Method for stimulating phagocytic activity and synergistic compositions therefor |
| US4303676A (en) * | 1980-03-21 | 1981-12-01 | Balazs Endre A | Hyaluronate based compositions and cosmetic formulations containing same |
| SU950735A1 (ru) * | 1980-10-28 | 1982-08-15 | Саратовский Ордена Трудового Красного Знамени Государственный Университет Им.Н.Г.Чернышевского | Способ получени гиалуроновой кислоты |
| US4517295A (en) * | 1983-02-18 | 1985-05-14 | Diagnostic, Inc. | Hyaluronic acid from bacterial culture |
| CA1238043A (en) * | 1983-12-15 | 1988-06-14 | Endre A. Balazs | Water insoluble preparations of hyaluronic acid and processes therefor |
| US4500676A (en) * | 1983-12-15 | 1985-02-19 | Biomatrix, Inc. | Hyaluronate modified polymeric articles |
| US4487865A (en) * | 1983-12-15 | 1984-12-11 | Biomatrix, Inc. | Polymeric articles modified with hyaluronate |
| US4629623A (en) * | 1984-06-11 | 1986-12-16 | Biomatrix, Inc. | Hyaluronate-poly (ethylene oxide) compositions and cosmetic formulations thereof |
| US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US4605691A (en) * | 1984-12-06 | 1986-08-12 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
-
1985
- 1985-03-12 US US06/710,929 patent/US4713448A/en not_active Expired - Lifetime
-
1986
- 1986-01-07 CA CA000499104A patent/CA1276143C/en not_active Expired - Lifetime
- 1986-01-20 GB GB08601304A patent/GB2172295B/en not_active Expired
- 1986-01-31 AU AU52891/86A patent/AU560956B2/en not_active Expired
- 1986-02-28 JP JP61045134A patent/JPS61207401A/ja active Granted
- 1986-03-06 BE BE0/216373A patent/BE904357A/fr not_active IP Right Cessation
- 1986-03-06 FR FR8603144A patent/FR2582002B1/fr not_active Expired
- 1986-03-10 DE DE3645191A patent/DE3645191C2/de not_active Expired - Lifetime
- 1986-03-10 IT IT19684/86A patent/IT1191981B/it active
- 1986-03-10 DE DE3645226A patent/DE3645226C2/de not_active Expired - Lifetime
- 1986-03-10 DE DE19863607897 patent/DE3607897A1/de active Granted
- 1986-03-11 SE SE8601135A patent/SE468830B/sv not_active IP Right Cessation
- 1986-03-11 CH CH992/86A patent/CH670092A5/fr not_active IP Right Cessation
- 1986-03-12 NL NLAANVRAGE8600644,A patent/NL186576C/xx not_active IP Right Cessation
-
1988
- 1988-12-21 JP JP63324696A patent/JPH01198602A/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1276143C (en) | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues | |
| US5099013A (en) | Hylan preparation and method of recovery thereof from animal tissues | |
| CA1230186A (en) | Cross-linked gels of hyaluronic acid and products containing such gels | |
| US4605691A (en) | Cross-linked gels of hyaluronic acid and products containing such gels | |
| Mathews | The interaction of collagen and acid mucopolysaccarides. A model for connective tissue | |
| US4636524A (en) | Cross-linked gels of hyaluronic acid and products containing such gels | |
| Partridge | The chemistry of connective tissues. 1. The state of combination of chondroitin sulphate in cartilage | |
| AU742675B2 (en) | Hyaluronic acid gel, method of its production and medical material containing it | |
| US3131130A (en) | Method of producing soluble collagen | |
| US4985552A (en) | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides | |
| Davies | Paper 7: properties of synovial fluid | |
| Fujii et al. | Isolation and characterization of a proteodermatan sulfate from calf skin | |
| CA1327569C (en) | Hylan preparation and method of recovery thereof from animal tissues | |
| EP0591181B1 (en) | Fractions of derivatized agarose and processes therefor | |
| HK1001897B (en) | Method for preparing hylan and novel hylan product | |
| KR100381408B1 (ko) | 저분자량 히알루론산나트륨의 제조 방법 | |
| JPH0586234B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| Armand et al. | Isolation and characterization of ichthyosan from tuna vitreous | |
| CN115703846A (zh) | 一种透明质酸衍生物的纯化方法 | |
| Illarionova et al. | Fibre, film, and porous materials based on chitosan | |
| Jackson | The Structural Stability of Tendon: A Physico-Chemical Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |